Kazakhstan begins clinical trials for its domestically developed COVID-19 vaccine
Kazakh Health Ministry granted permission to conduct the Phase 1/2 clinical trials of the domestically developed ‘QazCovid-in’ vaccine.
Human trials of the coronavirus vaccine in the country are conducted on healthy volunteers from 18 to 50 years old. 44 volunteers are participating in the Phase 1 of the clinical trials, which evaluates the safety of the vaccine candidate. The volunteers are the people who have not been previously infected with COVID-19 and did not develop the antibodies. 200 volunteers will be involved in the Phase 2 of the clinical trials, which is aimed at immunogenicity testing.
The clinical trials of the Kazakh COVID-19 vaccine will be conducted at the National Scientific Center of Phtisiopulmonology and the Center for Clinical Medicine and Research.
The World Health Organization has previously included Kazakhstan’s inactivated vaccine against COVID-19 in the list of candidate vaccines approved for clinical trials. The vaccine was developed on the basis of a strain of the novel coronavirus isolated from infected patients by the Research Institute for Biological Safety Problems of the Science Committee of Kazakh Ministry of Education and Science.